Posaconazole Tablet, Delayed Release
FDA Label NDC 69238-1476

53 label sections · Submitted to the FDA by Amneal Pharmaceuticals Ny Llc · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Amneal Pharmaceuticals Ny Llc for the product Posaconazole (NDC 69238-1476). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding 1.2 prophylaxis of invasive aspergillus and candida infections, 2.1 important administration instructions, 2.2 recommended dosage of posaconazole delayed-release tablets in adult patients, 2.3 recommended dosage of posaconazole delayed-release tablets for the prophylaxis of invasive aspergillus and candida infections in pediatric patients 2 years of age and older, 2.7 administration instructions for posaconazole delayed-release tablets, 2.9 non-substitutability between noxafil oral suspension and other formulations, 2.11 dosage modifications in patients with renal impairment, 3 dosage forms and strengths, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

* Please review the disclaimer below.